HC Wainwright Boosts Earnings Estimates for TG Therapeutics

TG Therapeutics, Inc. (NASDAQ:TGTX) – Equities researchers at HC Wainwright increased their FY2025 earnings per share (EPS) estimates for shares of TG Therapeutics in a report released on Wednesday, January 15th. HC Wainwright analyst E. White now expects that the biopharmaceutical company will post earnings per share of $1.26 for the year, up from their prior forecast of $1.17. HC Wainwright has a “Buy” rating and a $55.00 price target on the stock. The consensus estimate for TG Therapeutics’ current full-year earnings is $0.17 per share.

A number of other analysts also recently commented on TGTX. TD Cowen initiated coverage on TG Therapeutics in a research note on Tuesday, October 29th. They issued a “buy” rating and a $50.00 target price on the stock. StockNews.com upgraded shares of TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, January 7th. The Goldman Sachs Group raised their target price on TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. Finally, JPMorgan Chase & Co. upped their price target on TG Therapeutics from $30.00 to $43.00 and gave the stock an “overweight” rating in a report on Monday, November 25th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $40.67.

TG Therapeutics Stock Up 1.5 %

NASDAQ:TGTX opened at $30.18 on Thursday. TG Therapeutics has a 1-year low of $12.84 and a 1-year high of $36.84. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91. The firm has a market capitalization of $4.70 billion, a P/E ratio of -301.77 and a beta of 2.24. The company’s fifty day moving average price is $31.63 and its 200-day moving average price is $25.60.

TG Therapeutics (NASDAQ:TGTX) last released its earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 EPS for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.01). TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The firm had revenue of $83.90 million for the quarter, compared to analyst estimates of $81.68 million. During the same period last year, the firm earned $0.73 EPS. The company’s revenue for the quarter was down 49.4% compared to the same quarter last year.

Insiders Place Their Bets

In other TG Therapeutics news, CFO Sean A. Power sold 11,337 shares of TG Therapeutics stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $30.29, for a total transaction of $343,397.73. Following the sale, the chief financial officer now owns 670,632 shares of the company’s stock, valued at $20,313,443.28. The trade was a 1.66 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Sagar Lonial sold 5,000 shares of the stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $30.44, for a total transaction of $152,200.00. Following the completion of the sale, the director now owns 100,195 shares of the company’s stock, valued at approximately $3,049,935.80. The trade was a 4.75 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 26,358 shares of company stock worth $781,497. Corporate insiders own 10.50% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of TGTX. NBC Securities Inc. raised its stake in TG Therapeutics by 58.9% during the third quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 485 shares during the period. Blue Trust Inc. increased its holdings in shares of TG Therapeutics by 127.3% during the 3rd quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 849 shares during the last quarter. ORG Wealth Partners LLC purchased a new stake in shares of TG Therapeutics during the 3rd quarter valued at approximately $53,000. Values First Advisors Inc. acquired a new position in TG Therapeutics in the third quarter valued at approximately $58,000. Finally, GAMMA Investing LLC grew its position in TG Therapeutics by 562.4% in the fourth quarter. GAMMA Investing LLC now owns 2,557 shares of the biopharmaceutical company’s stock worth $77,000 after acquiring an additional 2,171 shares during the period. Institutional investors and hedge funds own 58.58% of the company’s stock.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.